reports
Quoin Pharmaceuticals Completes Merger and Will Commence Trading on Na...
Quoin Pharmaceuticals Completes Merger and Will Commence Trading on Nasdaq Capital Market under Ticker Symbol “QNRX” Concomitant Investment from Altium Capital Secured Ashburn, VA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals, Ltd., (NASDAQ: QNRX) (the “Company”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced the closing of its previously announced strategic merger with Cellect Biotechnology Ltd. Cellect concurrently completed the sale of the Company’s subsidiary, Cellect Biotherapeutics Ltd, to EnCellX, Inc., a privately held company...
Cellect Biotechnology Announces Record Date and Distribution Date for ...
Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals Tel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”) (the “Company”), announced today the record date and distribution date for the contingent value rights (the “CVRs”) to be distributed in connection with the previously announced strategic merger with privately-held Quoin Pharmaceuticals, Inc., a specialty pharmaceutical company focused on rare and orphan diseases (the “Merger”) and the sale of the Company’s subsidia...
Cellect Biotechnology Announces Shareholder Approval of Strategic Merg...
Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals Tel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held Quoin Pharmaceuticals, a specialty pharmaceutical company focused on rare and orphan diseases, and all other proposals presented at the Special General Meeting of shareholders held on September 26, 2021, including the sale of the Company’s subsidiary, Cellect Biotherapeutics Ltd, to EnCellX I...
Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantat...
Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S. Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX Tel Aviv, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: “APOP”), announced the first ApoGraftTM transplantation in a Leukemia patient in the Company’s clinical trial at Washington University in the U.S. ApoGraftTM is a product based on the Company’s cell selection technology designed to optimize immune therapy, in this ap...
Cellect Biotechnology Reports Second Quarter 2021 Financial and Operat...
Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results Strategic Merger Transaction Remains on Track to Close During the 2021 Third Quarter Tel Aviv, Israel, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2021, and provided an update on the proposed strategic merger with privately-held Quoin Pharmaceuticals and recent clinical news On Au...
The Securities and Exchange Commission Declared Cellect Biotechnology’...
The Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals Special General Meeting of Shareholders Scheduled for September 19, 2021 Tel Aviv, Israel, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced that its registration statement filed on Form F-4 with Securities and Exchange Commission (“SEC”) on August 10, 2...
Cellect Biotechnology Files Registration Statement in Connection with ...
Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals Transaction Expected to Close in the 2021 Third Quarter Tel Aviv, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced today that it has filed a registration statement, including a joint proxy statement/prospectus (“Proxy Statement”), with the Securities and Exchange Commission (SEC) in connection with its proposed strategic...
Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Tr...
Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial Results Support Ongoing Clinical Development of ApoGraft in U.S. Tel Aviv, Israel, April 19, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, today announced positive data from the Company's open label Phase 1/2 clinical trial of its ApoGraft™ technology in Israel. All eleven patients enrolled for the trial were transplanted using the ApoGraft product and were engrafted in a timely manner. The primary obj...
Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financ...
Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results TEL AVIV, Israel, March 29, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology that enables the functional selection of stem cells, today reported financial and operating results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. On March 24, the Company announced a strategic merger agreement with privately held Quoin Pharmaceuticals, a U.S. based specialty pharmaceutical company focused on rar...
Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Mer...
Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger Cellect shareholders to retain 25% of the combined Company pre-funding Tel Aviv, Israel and Ashburn, VA , March 24, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology that enables the functional selection of stem cells, and Quoin Pharmaceuticals Inc. (“Quoin”), a privately held specialty pharmaceutical company, today...
Cellect Biotechnology Reports Third Quarter Financial and Operating Re...
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021 Promising Progress on Clinical Development Progress, Collaborations and Partnering Mutually Ended Discussion on Medical Cannabis Commercial and Merger Agreements TEL AVIV, Israel, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the third quarter ended September 30, 2020. Subse...
Cellect Biotechnology Commences Collaboration with XNK Therapeutics to...
Cellect Biotechnology Commences Collaboration with XNK Therapeutics to Advance Novel NK Cell-Based Therapies; Adds Another Partner for its Functional Cell Selection Technology Tel Aviv, Israel , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Adding to a growing roster of partners, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced that it has entered into and commenced a collaborative development program with Sweden-based XNK Therapeutics, a pioneer in natural killer (NK) cell-based therapies. “This latest agreement demonstrates the continued progress and operational momentum we are continui...
Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft
Cellect Biotechnology Initiates U.S. Clinical Trial of ApoGraft Tel Aviv, Israel , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of cells facilitating safer and more efficacious cell and gene therapies, today announced that it has initiated its clinical trial in the U.S. to determine the safety and tolerability of the ApoGraft technology for bone marrow transplantations (BMT). The trial will enroll 18 patients and the primary end point of the study is overall incidence, frequency ...
Cellect Biotechnology Reports First Quarter 2020 Financial and Operati...
Cellect Biotechnology Reports First Quarter 2020 Financial and Operating Results; Continues to Demonstrate Significant Progress Despite Adjusted Operations Due to COVID-19 TEL AVIV, Israel, May 21, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the first quarter ended March 31, 2020 and provided an update on recent operating developments, including the status of the previously announced LOIs with Canndoc Ltd, a wholly owned su...
Cellect Biotechnology Announces Exercise of Warrants for Cash Proceeds...
Cellect Biotechnology Announces Exercise of Warrants for Cash Proceeds of Approximately $1.5 Million TEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the agreement by several investors to exercise certain warrants issued in February 2019 to purchase up to an aggregate of 534,160,000 ordinary shares represented by 534,160 American Depositary Shares (ADSs) having an original exercise price of $7.50 per ADS, at a reduced exercise price of $2...
Cellect Biotechnology Announces Receipt of Nasdaq Minimum Bid Price No...
Cellect Biotechnology Announces Receipt of Nasdaq Minimum Bid Price Notification Tel Aviv, Israel, May 16, 2019 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, announced today it has received notification from The Nasdaq Stock Market, LLC that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq...
Cellect Biotechnology to Explore Strategic Alternatives to Maximize Sh...
Cellect Biotechnology to Explore Strategic Alternatives to Maximize Shareholder Value Tel Aviv, Israel, May 16, 2019 (GLOBE NEWSWIRE) -- Following a review of its business, including the status of its clinical and development programs, resources and capabilities, Cellect Biotechnology Ltd. (Nasdaq: APOP) plans to explore strategic alternatives focused on maximizing shareholder value. Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, in-licensing, or other strategic transaction involving the Company or its...
Cellect Announces Closing of $6.5 Million Underwritten Public Offering
Cellect Announces Closing of $6.5 Million Underwritten Public Offering Tel Aviv, Israel, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced the closing of its previously announced $6.5 million underwritten public offering of 1,889,000 units, with each unit consisting of one American Depositary Share (ADS) and a warrant to purchase one ADS as well as 2,444,800 pre-funded units, with each pre-funded unit consisting of a pre-funded warrant to purchase one ADS and a warrant to purchase one ADS. ...
Cellect Announces Pricing of $6.5 Million Public Offering
Cellect Announces Pricing of $6.5 Million Public Offering Tel Aviv, Israel, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell production technology, today announced the pricing of an underwritten public offering of 1,889,000 units, with each unit consisting of one American Depositary Share (ADS) and a warrant to purchase one ADS as well as 2,444,800 pre-funded units, with each pre-funded unit consisting of a pre-funded warrant to purchase one ADS and a warrant to purchase one ADS. Each unit will be sold at $1.50 per unit a...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.